Nasdaq: LIMN

Liminatus Pharma, Inc. (LIMN)

Liminatus Pharma, Inc. is a public company that reports to the U.S. Securities and Exchange Commission and trades on Nasdaq under the ticker LIMN. Bright Analyst brings its financial statements, SEC filings, stock performance, news and peer comparisons together in one place, with AI analysis throughout.

Key facts

Ticker symbol
LIMN
Exchange
Nasdaq
SEC CIK
1971387
Official filings
SEC EDGAR

Research LIMN

  • Profile — Business description, headquarters, subsidiaries and corporate identifiers.
  • Financials — Income statement, balance sheet and cash flow from 10-K and 10-Q filings.
  • SEC Filings — Every 10-K, 10-Q and 8-K, readable inline with AI analysis.
  • Stock Analysis — Price chart, returns, technical indicators and related companies.
  • News — Latest headlines and press coverage.
  • Material Contracts — Material agreements filed as exhibits to SEC reports.
  • Benchmark — Stock performance against the S&P 500, Nasdaq-100 and Dow (through SPY, QQQ and DIA) and economic indicators.
  • Peer Comparison — Side-by-side financial ratios against industry peers.

Frequently asked questions

What is Liminatus Pharma, Inc.'s stock ticker?

Liminatus Pharma, Inc. trades under the ticker symbol LIMN on Nasdaq. Its SEC Central Index Key (CIK) is 1971387.

Where can I read Liminatus Pharma, Inc.'s SEC filings?

The LIMN SEC Filings page lists the 10-K annual reports, 10-Q quarterly reports and 8-K current reports Liminatus Pharma, Inc. has filed, with AI analysis. The original documents are also on SEC EDGAR.

How can I analyze LIMN's financial statements?

The LIMN Financials page shows Liminatus Pharma, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly, taken from its XBRL filings, with an AI analysis of each statement.

How does LIMN compare with its peers and the market?

The LIMN Peer Comparison page lines Liminatus Pharma, Inc. up against industry peers on valuation, growth and profitability ratios, and the Benchmark page compares its stock with the S&P 500, the Nasdaq-100 and the Dow.

For information only — not investment advice.